3′-Deoxy-3′-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients

被引:34
|
作者
Idema, Albert J. S. [1 ]
Hoffmann, Aswin L. [2 ,3 ]
Boogaarts, Hieronymus D. [1 ]
Troost, Esther G. C. [2 ,3 ]
Wesseling, Pieter [4 ,5 ]
Heerschap, Arend [6 ]
van der Graaf, Winette T. A. [7 ]
Grotenhuis, J. Andre [1 ]
Oyen, Wim J. G. [8 ]
机构
[1] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Dept Radiat Oncol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[4] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[5] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands
[6] Radboud Univ Nijmegen, Dept Radiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[7] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[8] Radboud Univ Nijmegen, Dept Nucl Med, Med Ctr, NL-6500 HB Nijmegen, Netherlands
关键词
PET/CT; F-18-fluorothymidine; FLT; high-grade glioma; overall survival; POSITRON-EMISSION-TOMOGRAPHY; IMAGING PROLIFERATION; MALIGNANT GLIOMA; F-18-FLT PET; BRAIN-TUMORS; NECK-CANCER; TRIAL; SEGMENTATION; GLIOBLASTOMA; BEVACIZUMAB;
D O I
10.2967/jnumed.112.105544
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a radiopharmaceutical depicting tumor cell proliferation with PET. In malignancies of the lung, breast, head and neck, digestive tract, brain, and other organs, quantitative assessment of F-18-FLT targeting has been shown to correlate with the proliferation marker Ki-67 and with clinical outcome measures such as time to progression and overall survival (OS). The aim of this study was to assess various PET segmentation methods to estimate the proliferative volume (PV) and their prognostic value for OS in patients with suspected high-grade glioma. Methods: Twenty-six consecutive patients underwent preoperative F-18-FLT PET/CT and T1-weighted MRI of the brain after contrast application. The maximum standardized uptake value (SUVmax) of all tumors was calculated, and 3 different segmentation methods for estimating the PV were used: the 50% isocontour of the SUVmax signal for the PV50%, the signal-to-background ratio (SBR) for an adaptive threshold delineation (PVSBR) method, and the iterative background-subtracted relative threshold level (RTL) method to estimate the PVRTL. The prognostic value of the SUVmax and the different PVs for OS were assessed. Results: Twenty-two patients had glioblastoma multiforme, 2 had anaplastic oligodendroglioma, 1 had anaplastic ependymoma, and 1 had anaplastic astrocytoma. The median OS was 397 d (95% confidence interval, 204-577); 19 patients died during the follow-up period. The PVSBR showed a significantly (P = 0.002) better association with OS than did SUVmax, PVRTL, and PV50%. Receiver-operating-characteristic analysis resulted in a threshold volume for the PVSBR of 11.4 cm(3), with a sensitivity and specificity of 70% and 83%, respectively, for the prediction of OS. Kaplan-Meier analyses showed a significant discrimination between short and long OS (P = 0.024, log rank) for this threshold. Conclusion: The PV as determined by F-18-FLT PET is associated with OS in high-grade malignant gliomas. The SBR method yielded the best results to predict short and long OS.
引用
收藏
页码:1904 / 1910
页数:7
相关论文
共 50 条
  • [21] [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors
    Choi, SJ
    Kim, JS
    Kim, JH
    Oh, SJ
    Lee, JG
    Kim, CJ
    Ra, YS
    Yeo, JS
    Ryu, JS
    Moon, DH
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (06) : 653 - 659
  • [22] [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors
    Seung Jin Choi
    Jae Seung Kim
    Jeong Hoon Kim
    Seung Jun Oh
    Jeong Gyo Lee
    Chang Jin Kim
    Young Shin Ra
    Jeong Seok Yeo
    Jin Sook Ryu
    Dae Hyuk Moon
    European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 : 653 - 659
  • [23] Using Radiolabeled 3′-Deoxy-3′-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung Cancer
    McHugh, Christopher, I
    Thipparthi, Monica R.
    Lawhom-Crews, Jawana M.
    Polin, Lisa
    Gadgeel, Shirish
    Akoury, Janice
    Mangner, Thomas J.
    Douglas, Kirk A.
    Li, Jing
    Ratnam, Manohar
    Shields, Anthony F.
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (10) : 1544 - 1550
  • [24] 3′-Deoxy-3′-[18F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer
    Chen, Haojun
    Li, Yimin
    Wu, Hua
    Sun, Long
    Lin, Qin
    Zhao, Long
    An, Hanxiang
    STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 (02) : 141 - 152
  • [25] Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model
    Schelhaas, Sonja
    Wachsmuth, Lydia
    Hermann, Sven
    Rieder, Natascha
    Heller, Astrid
    Heinzmann, Kathrin
    Honess, Davina J.
    Smith, Donna-Michelle
    Fricke, Inga B.
    Just, Nathalie
    Doblas, Sabrina
    Sinkus, Ralph
    Doering, Christian
    Schaefers, Klaus P.
    Griffiths, John R.
    Faber, Cornelius
    Schneider, Richard
    Aboagye, Eric O.
    Jacobs, Andreas H.
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (07) : 1063 - 1069
  • [26] Predictive Value of Early-Stage Uptake of 3′-Deoxy-3′-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation
    Lin, Chao
    Kume, Kyo
    Mori, Tetsuya
    Martinez, Miguel E.
    Okazawa, Hidehiko
    Kiyono, Yasushi
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) : 945 - 950
  • [27] Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
    Schoder, Heiko
    Zelenetz, Andrew D.
    Hamlin, Paul
    Gavane, Somali
    Horwitz, Steven
    Matasar, Matthew
    Moskowitz, Alison
    Noy, Ariela
    Palomba, Lia
    Portlock, Carol
    Straus, David
    Grewal, Ravinder
    Migliacci, Jocelyn C.
    Larson, Steven M.
    Moskowitz, Craig H.
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (05) : 728 - 734
  • [28] 3′-DEOXY-3′-[18F]FLUOROTHYMIDINE PET QUANTIFICATION OF BONE MARROW RESPONSE TO RADIATION DOSE
    McGuire, Sarah M.
    Menda, Yusuf
    Ponto, Laura L. Boles
    Gross, Brandie
    Buatti, John
    Bayouth, John E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : 888 - 893
  • [29] 3′-deoxy-3′-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors:: Comparison with 2-deoxy-2-18F-fluoro-D-glucose
    Yamamoto, Yuka
    Nishiyama, Yoshihiro
    Ishikawa, Shinya
    Gotoh, Masashi
    Bandoh, Shuji
    Kanaji, Nobuhiro
    Asakura, Masato
    Ohkawa, Motoomi
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2008, 32 (03) : 432 - 437
  • [30] In Vivo Imaging of Cell Proliferation Enables the Detection of the Extent of Experimental Rheumatoid Arthritis by 3′-Deoxy-3′-18F-Fluorothymidine and Small-Animal PET
    Fuchs, Kerstin
    Kohlhofer, Ursula
    Quintanilla-Martinez, Leticia
    Lamparter, Denis
    Koetter, Ina
    Reischl, Gerald
    Roecken, Martin
    Pichler, Bernd J.
    Kneilling, Manfred
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (01) : 151 - 158